Prostate Cancer Screening Every 5 Years Can Save Lives

Men with prostate specific antigen (PSA) levels between 1.5-3 ng/ml were deemed intermediate risk for prostate cancer and reevaluated in two years.

A simple and easy blood test assessing prostate-specific antigen (PSA), a key marker for prostate cancer was found to be both safe and effective when conducted every five years ().

Undergoing a straightforward blood test to detect prostate-specific antigen (PSA), a critical marker for prostate cancer, every five years, stands as a safe and effective measure with profound potential to safeguard one’s health.

Biochemical Recurrence of Prostate Cancer
Biochemical recurrence (BCR) of prostate cancer is a condition that occurs in men who have previously been cured of prostate cancer. In BCR, prostate-specific antigen (PSA) is elevated above normal.

‘Men with PSA levels under 1.5 ng/ml were considered low risk and retested after five years. #prostatecancer #prostatehealth’

PSA Screening for Prostate Cancer

Screening for prostate cancer has historically been a controversial subject. While the PSA test has been effective in screening the risk, it is also known for false positives leading to unnecessary invasive treatments and false negatives leading to cancers being missed."

This is gradually changing due to MRI scans which can avoid unnecessary biopsies and the use of ’active surveillance’, where men with early-stage cancer are monitored and only undergo treatment if their disease progresses," said the researchers from Heinrich-Heine University, Dusseldorf in Germany.

The team’s study, presented at the ongoing European Association of Urology (EAU) Congress in Paris, France, showed that five years is enough to screen low-risk men for prostate. They noted that the "screening interval for those at low risk could be much longer with minimal additional risk".

Brachytherapy for Prostate Cancer
Learn about two different types of brachytherapy used for treating prostate cancer. Get information on the latest advances in the field.

The findings come as a new analysis published in the Lancet Commission showed that cases of prostate cancer are likely to double worldwide to 2.9 million per year, while annual deaths are projected to rise by 85 percent -- to almost 700,000 deaths by 2040.The new study included men aged 45 split into three groups.

While those with a PSA level between 1.5-3 ng/ml were deemed intermediate risk and followed up in two years, men with a PSA level over 3 ng/ml were found in the high-risk category and given an MRI scan and biopsy.

Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it’s too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as ...

Of over 20,000 men recruited to the trial and deemed low risk, 12,517 have now had their second PSA test at age 50.The results, also forthcoming in the journal European Urology, showed that only 1.2 percent of these (146 in total) had high levels of PSA (over 3 ng/ml) and were referred for an MRI and biopsy. Only 16 of these men were subsequently found to have cancer -- just 0.13 percent of the total cohort.

"By raising the bar for low risk from 1 ng/ml to 1.5, we enabled 20 percent more men within our cohort to have a longer gap between tests, and very few contracted cancer in that time," said lead researcher Professor Peter Albers, from the Department of Urology at the University.

Surgery of prostate gland - Animation
Interactive section of Medindia gives information regarding Surgery of prostate gland

"Our study is still underway, and we may find that an even longer screening interval, of seven, eight, or even ten years, is possible without additional risk," he added.

Reference:

Five-year interval is safe for prostate cancer screening, research shows - (https://uroweb.org/press-releases/bladder-cancer-treatment-can-be-better-targeted-and-more-effective-trials-show-3-2)

Source-IANS